Alligator Bioscience AB (publ) Interim report January-June 2019
"The results that Janssen presented at ASCO show that ADC-1013 can be administered in considerably higher doses than any of the other CD40 antibodies in clinical development. [...] The study also shows early signs of clinical efficacy", CEO Per Norlén comments.
https://lnkd.in/g_-SFuj
https://lnkd.in/g-PW2df #immunooncology
"The results that Janssen presented at ASCO show that ADC-1013 can be administered in considerably higher doses than any of the other CD40 antibodies in clinical development. [...] The study also shows early signs of clinical efficacy", CEO Per Norlén comments.
https://lnkd.in/g_-SFuj
https://lnkd.in/g-PW2df #immunooncology
